BRCA2 p.Ser2670Leu
Variant summary
The NM_000059.4(BRCA2):c.8009C>T (p.Ser2670Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a cumulative frequency of 0.00000248 (AC=4) in the gnomAD database across 1,613,428 control chromosomes (no homozygotes observed). The grpmax filtering allele frequency (95% CI) is 0.000208. In-silico predictor (REVEL) classifies this variant as likely damaging/oncogenic. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. The affected nucleotide is highly conserved across species (PhyloP 100-way vertebrate score: 7.50). Variant has been reported in ClinVar as Pathogenic/Likely Pathogenic (★★). ClinVar reports functional evidence for this variant: "SCV000073398: Experimental studies have shown that this missense change affects BRCA2 function (PMID:19043619, 29394989, 32444794)." and additional evidence is available in ClinVar. A different missense at the same amino acid position has been reported as Pathogenic/Likely Pathogenic in ClinVar: p.S2670W: Pathogenic (ClinVar VariationId 489785, 3 stars) Other variants at the same amino acid position have been reported in ClinVar (not pathogenic): p.S2670P: Uncertain_significance (ClinVar VariationId 1001575, 2 stars); p.S2670= (synonymous): Likely_benign (ClinVar VariationId 183837, 3 stars) This exact variant is curated in the UniProt human variants database as Uncertain Significance; it is also listed as a COSMIC curated somatic variant.
Frequency
Consequence
NM_000059.4 missense
Scores
Clinical Significance
Conservation
Publications
- BRCA2-related cancer predispositionInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- breast-ovarian cancer, familial, susceptibility to, 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
- Fanconi anemia complementation group D1Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
- pancreatic cancer, susceptibility to, 2Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- sarcomaInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- hereditary breast ovarian cancer syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- medulloblastomaInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
Classification according to ACMG Germline Pathogenicity v2019
Our verdict: Pathogenic. The variant received 12 points.
| Apply | Criterion Code & Title / Strength | Rationale / Clinical Context | |
|---|---|---|---|
| PS3Functional studies show damaging effect | Well-established functional study supports damaging effect (PS3); SCV000073398: Experimental studies have shown that this missense change affects BRCA2 function (PMID: 19043619, 29394989, 32444794).; SCV001426773: "The most pronounced variant effect results in loss of homology directed DNA repair (HDR) capability (Hart_2019, Guidugli_2018, Karchin_2008)."; SCV001478293: In the VarCall Bayesian statistical model for VUS classification using functional assay data (Guidugli et al Am J Hum Genet 2018; 102:233-248, Couch Lab), the variant has a probability of being deleterious of 0.99 and an overall classification of pathogenic. (PS3_strong).; SCV000186012: "This variant was found to be functionally defective in a homology-directed repair assay (Karchin R et al. Cancer Inform. 2008 Apr;6:203-16; Guidugli L et al. Am. J. Hum. Genet. 2018 Jan; Hart SN et al. Genet. Med., 2019 01;21:71-80)."; SCV000683935: Functional studies reported this variant results in the production of BRCA2 protein that is severely impaired in homology-directed repair assays (PMID: 19043619, 29394989). An RNA study found the variant resulted in splicing defects predicted to cause an absent or non-functional protein product (PMID: 31843900).; SCV000210458: Published functional studies demonstrate a damaging effect: impaired homology directed repair activity and sensitivity to PARP inhibitors (PMID: 29394989, 29884841, 32444794).; SCV000889147: Experimental studies indicate that this variant has a damaging effect on the expression and function of the BRCA2 protein in vitro (PMID: 31843900 (2019), 29394989 (2018), 28339459 (2017), 19043619 (2008)).; SCV000592170: Through a homology-directed DNA repair assay, the p.Ser2670Leu variant was found to substantially decrease HDR compared to wild-type BRCA2 and known neutral variants, and was predicted to be deleterious (Guidugli_2017_PMID:29394989).; SCV005346982: "studies using a homology directed DNA repair activity assay showed this variant is functionally defective" (Hart et al. 2018. PubMed ID: 29884841; Guidugli et al. 2012. PubMed ID: 23108138). | ||
| PM5Novel missense at known pathogenic residue | Different pathogenic missense at same AA residue in ClinVar (PM5); ClinVar contains a germline Pathogenic/Likely Pathogenic entry at the same amino acid position with a different amino acid change: p.S2670W: Pathogenic (ClinVar VariationId 489785, 3 stars); Other variants at the same amino acid residue (not pathogenic): p.S2670P: Uncertain_significance (ClinVar VariationId 1001575, 2 stars); p.S2670= (synonymous): Likely_benign (ClinVar VariationId 183837, 3 stars) | ||
| PP3Computational evidence supports damaging effect | Germline meta computational scorer (REVEL/MetaRNN/BayesDel) predicts damaging effect — moderate evidence (PP3); Splicing verdict: not pathogenic.; Germline computational verdict: pathogenic (Moderate). | ||
| PP5Reputable source reports pathogenic | ClinVar 2-star pathogenic — strong (PP5); ClinVar submissions overwhelmingly pathogenic (≥10 total, ≥80% P/LP, <10% B/LB) — strong (PP5, count-based); ClinVar germline classification: Pathogenic/Likely Pathogenic, 2 star(s). ClinVar submissions strongly and reliably favor pathogenicity (22/23 total P/LP). |
Variant Effect in Transcripts
Automated classification analysis was done for transcript: NM_000059.4. You can select a different transcript below to see updated classification assignments.
RefSeq Transcripts
| Sel. | Gene / Transcript | Tags | HGVSc / HGVSp | Effect | Exon rank | Protein / UniProt |
|---|---|---|---|---|---|---|
BRCA2 | MANE Select | c.8009C>T p.Ser2670Leu | missense | Exon 18 of 27 | Prot: NP_000050.3 UniProt: | |
BRCA2 | c.8009C>T p.Ser2670Leu | missense | Exon 18 of 27 | Prot: NP_001419006.1 UniProt: | ||
BRCA2 | c.8009C>T p.Ser2670Leu | missense | Exon 18 of 27 | Prot: NP_001393649.1 UniProt: |
Ensembl Transcripts
| Sel. | Gene / Transcript | Tags | HGVSc / HGVSp | Effect | Exon rank | Protein / UniProt |
|---|---|---|---|---|---|---|
BRCA2 | TSL:5MANE Select | c.8009C>T p.Ser2670Leu | missense | Exon 18 of 27 | Prot: ENSP00000369497.3 UniProt: | |
BRCA2 | TSL:1 | c.8009C>T p.Ser2670Leu | missense | Exon 18 of 27 | Prot: ENSP00000439902.1 UniProt: | |
BRCA2 | TSL:1 | c.7640C>T p.Ser2547Leu | missense | Exon 18 of 27 | Prot: ENSP00000499438.2 UniProt: |
Frequencies
Allele frequencies (AF), counts (AC/AN), homozygotes and coverage
| Source / population | AF | AC | Hom | AN | Coverage |
|---|---|---|---|---|---|
Global population databases 4 sources | |||||
GnomAD3 genomes | AF: 0.0000132 | AC:2 | Hom:0 | AN:151936 | Cov:32 |
GnomAD4 exome Warning | AF: 0.00000137 | AC:2 | Hom:0 | AN:1461492 | Cov:31 |
GnomAD4 genome | AF: 0.0000132 | AC:2 | Hom:0 | AN:151936 | Cov:32 |
ALFA (dbGaP/dbSNP Allele Frequency Aggregator) | AF: 0.00 | AC:0 | Hom:0 | AN:200630 | |
Case/control cohorts
| Cohort | Cases | Controls | ||||
|---|---|---|---|---|---|---|
| AF | AC | AN | AF | AC | AN | |
SCHEMA | 0.0000172 | 1 | 58190 | 0.00 | 0 | 80498 |
ClinVar
Computational Scores
| Algorithm | Calibrated pred. | Score | Prediction |
|---|---|---|---|
AlphaGenome AVI | Pathogenic | 27 | |
AlphaMissense | Pathogenic | 0.72 | |
BayesDel_addAF | Pathogenic | 0.39 | D |
BayesDel_noAF | Pathogenic | 0.32 | |
CADD | Pathogenic | 28 | |
DANN | Pathogenic | 1.0 | |
Eigen | Pathogenic | 0.86 | |
Eigen_PC | Pathogenic | 0.79 | |
FATHMM_MKL | Pathogenic | 0.99 | D |
FuncVEP CTI | Pathogenic | 0.83 | |
GPN-Star LLR | N/A | -5.9 | |
GPN-Star score | N/A | 5.9 | |
M_CAP | Pathogenic | 0.36 | D |
MetaRNN | Pathogenic | 0.93 | D |
MetaSVM | Uncertain | 0.73 | D |
Mutation Taster | N/A | 25/75 | disease causing (ClinVar) |
PhyloP100 | Uncertain | 7.5 | |
PrimateAI | Benign | 0.47 | T |
PROVEAN | Benign | -1.8 | N |
RBP_binding_hub_radar | N/A | 0.0 | |
RBP_regulation_power_radar | N/A | 1.7 | |
REVEL | Pathogenic | 0.86 | |
Sift | Uncertain | 0.0010 | D |
Sift4G | Uncertain | 0.0030 | D |
VESM-3B | Benign | -11 |
Splicing Scores
| Algorithm | Calibrated pred. | Score | Prediction |
|---|---|---|---|
Pangolin (max) | Benign | 0.020 | |
SpliceAI score (max) | Benign | 0.010 | Details are displayed if max score is > 0.2 |
Splicevardb | N/A | 3.0 |
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.
MaveDB functional evidence
- Gene
- BRCA2
- Assay type
- Reporter
- Mechanism
- DNA repair and Double-strand break repair via homologous recombination
- Model system
- Other (Cricetulus griseus)
- Score
- 0.976 · p.Ser2670Leu (assay numbering)